Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children

Autor: [No Value] Groothuis, Gr Siber, Wj Rodriguez, Vg Hemming, Ga Prince, Julita O. Arrobio, Mj Levin, Fulton, Ce Long, Rc Welliver, Hc Meissner, M Vanraden, Cb Hall, Da Tristram, Eaf Simoes

Publikováno v: New England Journal of Medicine. 329:1524-1530

Background Infants with cardiac disease or prematurity are at risk for severe illness caused by respiratory syncytial virus. Immune globulin with a high titer of antibodies against respiratory syncytial virus may offer infants and young children at r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0ba65f5f1abfc5d4bc5b15f1328201ea
https://doi.org/10.1056/nejm199311183292102

The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analyses.

Autor: Fisman D; Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada., Giglio N; Servicio de Consultorios Externos de Pediatría. Hospital de Niños Ricardo Gutiérrez, Ciudad Autónoma de Buenos Aires, Argentina., Levin MJ; Departments of Pedatrics and Medicine, University of Colorado School of Medicine, Denver, Colorado, United States., Nguyen VH; VNH Consulting, Montreal, Québec, Canada., Pelton SI; Department of Health Sciences, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA., Postma M; Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.; Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia.; Faculty of Economics & Business, University of Groningen, Groningen, The Netherlands.; Department of Pharmacology and Therapy, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia., Ruiz-Aragón J; Hospital de la Línea de la Concepción, Cádiz, Spain., Urueña A; Centro de Estudios para la Prevención y Control de Enfermedades Transmisibles, Universidad Isalud, Buenos Aires, Argentina., Mould-Quevedo JF; CSL Seqirus Inc., Summit, New Jersey, USA.

Publikováno v: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2024 Dec 31; Vol. 20 (1), pp. 2351675. Date of Electronic Publication: 2024 Jun 04.

A Clinical and Economic Comparison of Cell-Based Versus Recombinant Influenza Vaccines in Adults 18-64 Years in the United States.

Autor: Levin MJ; Departments of Pediatrics and Medicine, Anschutz Medical Campus, University of Colorado, Aurora, CO 80045, USA., Rawashdh NA; Real-World Solutions, IQVIA, Falls Church, VA 22042, USA., Mofor L; CSL Seqirus USA, Summit, NJ 07901, USA., Anaya P; Real-World Solutions, IQVIA, Falls Church, VA 22042, USA., Zur RM; Real-World Solutions, IQVIA, Falls Church, VA 22042, USA., Kahn EB; Real-World Solutions, IQVIA, Falls Church, VA 22042, USA., Yu D; CSL Seqirus Australia, Melbourne 3052, Australia., Mould-Quevedo JF; CSL Seqirus USA, Summit, NJ 07901, USA.

Publikováno v: Vaccines [Vaccines (Basel)] 2024 Oct 26; Vol. 12 (11). Date of Electronic Publication: 2024 Oct 26.

Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials.

Autor: Levin MJ; University of Colorado School of Medicine, Aurora, CO, USA., Ustianowski A; North Manchester General Hospital, Manchester, UK., De Wit S; Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium., Beavon R; Vaccines and Immune Therapies, AstraZeneca, BioPharmaceuticals R&D, Cambridge, UK., Thissen J; Vaccines and Immune Therapies, AstraZeneca, BioPharmaceuticals R&D, Cambridge, UK., Seegobin S; Vaccines and Immune Therapies, AstraZeneca, BioPharmaceuticals R&D, Cambridge, UK., Dey K; Vaccines and Immune Therapies, AstraZeneca, BioPharmaceuticals R&D1 Medimmune Way, Gaithersburg, MD, 20878, USA., Near KA; Vaccines and Immune Therapies, AstraZeneca, BioPharmaceuticals R&D1 Medimmune Way, Gaithersburg, MD, 20878, USA., Streicher K; Vaccines and Immune Therapies, AstraZeneca, BioPharmaceuticals R&D1 Medimmune Way, Gaithersburg, MD, 20878, USA., Kiazand A; Patient Safety, Chief Medical Office, R&D and Vaccines and Immune Therapies, AstraZeneca, Gaithersburg, MD, USA., Esser MT; Vaccines and Immune Therapies, AstraZeneca, BioPharmaceuticals R&D1 Medimmune Way, Gaithersburg, MD, 20878, USA. mark.esser@astrazeneca.com.

Publikováno v: Infectious diseases and therapy [Infect Dis Ther] 2024 Jun; Vol. 13 (6), pp. 1253-1268. Date of Electronic Publication: 2024 May 04.

A clinical and economic assessment of adjuvanted trivalent versus standard egg-derived quadrivalent influenza vaccines among older adults in the United States during the 2018-19 and 2019-20 influenza seasons.

Autor: Levin MJ; Departments of Pediatrics and Medicine, Anschutz Medical Campus, University of Colorado, Aurora, CO, USA., Divino V; Real World Solutions, IQVIA, Falls Church, VA, USA., Postma MJ; Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.; Department of Economics, Econometrics and Finance, Faculty of Economics and Business, University of Groningen, Groningen, The Netherlands.; Centre of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia., Pelton SI; Department of Pediatrics, Boston University School of Medicine, Boston, MA, USA.; Division of Pediatric Infectious Diseases, Maxwell Finland Laboratory, Boston Medical Center, Boston, MA, USA., Zhou Z; Real World Solutions, IQVIA, Falls Church, VA, USA., DeKoven M; Real World Solutions, IQVIA, Falls Church, VA, USA., Mould-Quevedo J; Global Health Economics and Value Strategy, CSL Seqirus Inc, Summit, NJ, USA.

Publikováno v: Expert review of vaccines [Expert Rev Vaccines] 2024 Jan-Dec; Vol. 23 (1), pp. 124-136. Date of Electronic Publication: 2023 Dec 19.